Cel-sci reports phase 3 tumor pd-l1 biomarker data demonstrate multikine's increased efficacy and points to potential for combination with checkpoint inhibitors for head & neck cancer

Vienna, va.--(business wire)---- $cvm #ahns2023--cel-sci reports phase 3 tumor pd-l1 biomarker data demonstrate multikine's increased efficacy and potential for combination with checkpoint inhibitors.
CVM Ratings Summary
CVM Quant Ranking